Please login to the form below

Not currently logged in
Email:
Password:

Hutchison MediPharma

This page shows the latest Hutchison MediPharma news and features for those working in and with pharma, biotech and healthcare.

Lilly enters cancer collaboration in China

Lilly enters cancer collaboration in China

Lilly will work with Chi-Med's research-focused subsidiary Hutchison MediPharma to investigate fruquintinib (HMPL-013), a small molecule to inhibit the vascular endothelial growth factor (VEGF) receptor tyrosine kinases. ... Both companies will share

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Asset acquisition. Mesenchymal stem cell business, including Prochymal (approved). 100. †Hutchison MediPharma / Eli Lilly.

  • Pharma deals during October 2013 Pharma deals during October 2013

    Focusing on China, Lilly has entered into a licence and co-development agreement with Hutchison MediPharm a for fruquintinib (HMPL-013), a phase II inhibitor of all three forms of Vascular ... Hutchison MediPharma will continue the development of

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics